Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Opinion|Videos|November 15, 2024
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations
Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.
Advertisement
- All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
- Encorafenib + binimetinib (
Riely GJ, et al. J Clin Oncol. 2023 ) - Dabrafenib + trametinib (
Planchard D, et al. J Thorac Oncol. 2022 )
- Encorafenib + binimetinib (
- Have any new safety signals emerged from long-term follow-up?
- Encorafenib + binimetinib (
Smit E, et al. 2024.WCLC. MA06.13 - Encorafenib + binimetinib (
Riely G, et al. 2024.ESMO.LBA56 )- Impression of overall survival data
- Impact on clinical practice
- Difference in responses in first line vs second line
- Encorafenib + binimetinib (
- How do you choose between different BRAF-MEK inhibitor
- Based on the recent data presented at ESMO, how do you approach dose modifications?
- First-line immunotherapy vs BRAF and MEK inhibitors (
Di Federico A, et al. 2024. ESMO. Abstract 1299p ) - Treatment sequences in BRAF-V600 mutant (
Wiesweg M, et al. 2024. ESMO Abstract 1300p
Advertisement
Related to this article
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for early-stage cutaneous melanoma.
Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
5